M&T Bank Corp Makes New $315,000 Investment in Amedisys, Inc. (NASDAQ:AMED)

M&T Bank Corp acquired a new position in Amedisys, Inc. (NASDAQ:AMED - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 3,414 shares of the health services provider's stock, valued at approximately $315,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Hexagon Capital Partners LLC lifted its holdings in Amedisys by 108.1% in the first quarter. Hexagon Capital Partners LLC now owns 310 shares of the health services provider's stock valued at $29,000 after acquiring an additional 161 shares during the last quarter. MassMutual Private Wealth & Trust FSB lifted its position in Amedisys by 56.1% in the first quarter. MassMutual Private Wealth & Trust FSB now owns 334 shares of the health services provider's stock valued at $31,000 after purchasing an additional 120 shares during the period. Fifth Third Bancorp increased its holdings in Amedisys by 68.1% in the first quarter. Fifth Third Bancorp now owns 348 shares of the health services provider's stock valued at $32,000 after buying an additional 141 shares in the last quarter. UMB Bank n.a. raised its position in shares of Amedisys by 100.0% during the 1st quarter. UMB Bank n.a. now owns 386 shares of the health services provider's stock worth $36,000 after purchasing an additional 193 shares during the last quarter. Finally, Johnson Financial Group Inc. purchased a new stake in Amedisys in the 4th quarter worth approximately $55,000. Institutional investors and hedge funds own 94.36% of the company's stock.

Amedisys Price Performance

NASDAQ AMED opened at $97.47 on Friday. Amedisys, Inc. has a 52 week low of $82.15 and a 52 week high of $98.95. The company has a current ratio of 1.29, a quick ratio of 1.29 and a debt-to-equity ratio of 0.27. The stock has a market cap of $3.20 billion, a price-to-earnings ratio of 35.97, a price-to-earnings-growth ratio of 1.32 and a beta of 0.94. The company has a 50-day moving average price of $95.97 and a two-hundred day moving average price of $93.69.

Amedisys (NASDAQ:AMED - Get Free Report) last posted its earnings results on Wednesday, April 23rd. The health services provider reported $1.25 EPS for the quarter, topping the consensus estimate of $1.13 by $0.12. Amedisys had a net margin of 3.79% and a return on equity of 12.52%. The firm had revenue of $594.78 million during the quarter, compared to analysts' expectations of $597.43 million. During the same quarter in the prior year, the firm earned $1.03 EPS. Amedisys's quarterly revenue was up 4.1% on a year-over-year basis. Analysts forecast that Amedisys, Inc. will post 4.4 EPS for the current year.

Wall Street Analysts Forecast Growth

AMED has been the subject of several recent analyst reports. Wall Street Zen cut shares of Amedisys from a "strong-buy" rating to a "buy" rating in a research note on Saturday, May 24th. Royal Bank Of Canada reiterated an "outperform" rating and issued a $100.00 price objective on shares of Amedisys in a report on Wednesday, April 16th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $100.75.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.